For the quarter ending 2025-09-30, IMCR had $2,662K increase in cash & cash equivalents over the period. -$5,204K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue | 103,693 | - |
| Cost of revenue from sale of therapies | 4,255 | - |
| PRAMEPrograms | 97,933 | - |
| Tebentafusp Programs | 48,603 | - |
| Infectious Disease Programs | 6,807 | - |
| Other Clinical And Pre Clinical Costs | 68,519 | - |
| R&d expenses-External RD | 221,862 | - |
| R&d expenses-Salaries And Other Employee Related Cost | 59,832 | - |
| Sg&a expenses-Salaries And Other Employee Related Cost | 64,128 | - |
| Sg&a expenses-Other Selling General And Administrative Expenses | 103,913 | - |
| Other segment (expense) income, net | 44,124 | - |
| Net loss | -177 | -5,277 |
| Share-based compensation expense | 9,837 | 19,522 |
| Depreciation | 798 | 1,634 |
| Unrealized foreign exchange gains, net | 9,622 | 607 |
| Unrealized gains on marketable securities | 5,062 | 10,162 |
| Non-cash lease expense | 567 | 1,114 |
| Other | -527 | -1,049 |
| Increase in accounts receivable | 5,989 | 3,341 |
| Increase in prepayments and other current assets | 6,089 | -365 |
| (decrease) increase in accounts payable | -287 | -3,587 |
| Increase in accrued expenses | 15,133 | 22,787 |
| Decrease in deferred revenue | -146 | -97 |
| Increase (decrease) in operating lease liabilities | 1,052 | -528 |
| Increase in other operating assets | 4,998 | -3,527 |
| Increase in other operating liabilities | 0 | 0 |
| Net cash provided by operating activities | -4,456 | 26,399 |
| Purchase of marketable securities | 0 | 30,000 |
| Proceeds from sale of marketable securities | 6,000 | 10,000 |
| Purchase of property and equipment | 748 | 712 |
| Net cash used in investing activities | 5,252 | -20,712 |
| Proceeds from exercise of share options | 1,866 | 6,221 |
| Proceeds from issue of convertible senior notes | 0 | 0 |
| Payments for debt issuance costs | 0 | 0 |
| Net cash provided by financing activities | 1,866 | 6,221 |
| Increase in cash and cash equivalents | 2,662 | 11,908 |
| Effect of exchange rate changes on cash | 28,112 | - |
| Cash and cash equivalents at beginning of period | 455,731 | - |
| Cash and cash equivalents at end of period | 498,413 | - |
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)